Employees: 1,033
Size Bliss GVS Pharma (BLISSGVS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $777M, the 689th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹680.35 on 18 Nov 2026.
Performance Over six months the shares gained 140.6%, against -7.0% for the median peer and +3.8% for the India market (cap-weighted) — highest of 19 in its peer set.
Growth Revenue grew 24.9% over the last twelve months (peer median +5.2%); the operating margin is 18.5% (peer median 8.9%).
Valuation It trades at 6.7× enterprise value to sales against a peer median of 2.5× (4th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 34% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +24 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.5 points below its cost of capital (12.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹10.7B | ₹9.21B | ₹8.02B | ₹7.66B | ₹7.47B |
| Revenue growth | — | +15% | +5% | +2% | — |
| Gross profit | ₹4.28B | ₹3.07B | ₹2.33B | ₹2.49B | ₹2.33B |
| EBITDA | ₹2.36B | ₹1.66B | ₹1.23B | ₹1.49B | ₹1.17B |
| Net income | ₹1.61B | ₹1.29B | ₹843M | ₹755M | ₹709M |
| Free cash flow | n/a | ₹839M | ₹392M | ₹734M | -₹525M |
| Capital expenditure | n/a | ₹568M | ₹763M | ₹283M | ₹938M |
| Total debt | ₹226M | ₹218M | ₹881M | ₹998M | ₹1.02B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BLISSGVS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.5% | -3.8% | 6th highest of 19 |
| 6-month return | +140.6% | -7.0% | highest of 19 |
| Distance from 52-week high | -8.1% | -33.9% | 2nd highest of 19 |
| Revenue growth (TTM) | +24.9% | +5.2% | 4th highest of 19 |
| Operating margin | 18.5% | 8.9% | 6th highest of 19 |
| EV / Sales | 6.7× | 2.5× | 4th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 33.9% | 1.5% | most demanding of 12 |
| Growth delivered (Del g) | +10.1% | +0.5% | 5th highest of 12 |
| Hurdle (Req g minus delivered) | +23.8 pp | -3.1 pp | 2nd most demanding of 12 |
| ROIC minus cost of capital | -0.5 pp | +1.2 pp | 7th lowest of 17 |
| EV / EBITDA | 30.4× | 9.7× | most expensive of 7 |
| Net debt / EBITDA | -0.5× | -0.5× | 4th least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | 6.7× | 33.9% | +10.1% |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | 0.3× | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | 0.9× | -3.8% | -0.8% |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 1.6× | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | 3.1× | -2.5% | +2.6% |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | 16.7× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $765M | +40% | -2% | 15% | 2.4× | 0.3% | +0.5% |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 2.6× | n/a | n/a |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 1.8× | 6.6% | +17.7% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 4.1× | 16.3% | -8.7% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | 2.5× | 13.5% | -0.2% |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 2.5× | 1.5% | +22.1% |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 3.1× | 13.9% | +27.7% |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | 789.4× | n/a | n/a |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | 5.3× | 9.4% | -1.4% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | 28.6× | n/a | n/a |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 2.3× | -2.6% | +20.3% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | 1.4× | -2.1% | 0.0% |